Posted by Michael Wonder on 01 May 2024
Pembrolizumab for the treatment of patients 3 years and older with relapsed or refractory classical Hodgkin's lymphoma
1 May 2024 - NICE has published updated evidence-based recommendations on the pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory classical Hodgkin's lymphoma.
Pembrolizumab is recommended as an option for the treatment of patients 3 years and older with relapsed or refractory classical Hodgkin's lymphoma who have had at least 2 previous treatments and cannot have an autologous stem cell transplant.
